Article | March 15, 2024

FDA's Push For Diversity: Addressing Data Challenges In Clinical Trials Through Updated Race And Ethnicity Guidance

Source: Citeline

By Lya Rebelo, Manager, Commercial Enablement

GettyImages-1357830750 diversity

The US Food and Drug Administration (FDA) has introduced draft guidance to foster diversity in clinical trials. This updated version, which replaces the 2016 guidance, offers standardized suggestions for gathering and reporting race and ethnicity data in clinical trials for FDA-regulated medical products. The initiative is designed to ensure that clinical research is inclusive and representative of diverse populations.

Furthermore, the updated guidance broadens its reach to encompass non-interventional studies and interventional clinical trials. It encourages compliance with the 1998 final rule on the presentation of demographic data in new drug applications and the collection of race and ethnicity data in biologics license applications and medical device applications. The FDA is welcoming public feedback on the draft guidance until April 29, 2024. This step is crucial in ensuring that the benefits and risks of medical products are accurately assessed for all population groups, thus promoting health equity.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader